Roberto Pili
Associate Dean for Cancer Research and Integrative Oncology · University at Buffalo School of Medicine
Credentials: · · · ·
History
- Present
Division of Hematology/Oncology in the Department of Medicine · University at Buffalo School of Medicine
1992–1994- 1989–1992
Internal Medicine
- 1985–1989
Catholic University School of Medicine, Summa Cum Laude
Research
Journal of Clinical Oncology · 2009 · 1,813 citations
Laboratory Investigation · 1992 · 744 citations
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth
Proceedings of the National Academy of Sciences of the United States of America · 2008 · 543 citations
- MC
47 papers
- ME
16 papers
15 papers · 7 as a fellow
- JE
14 papers
- RM
12 papers
- MM
11 papers
11 papers
10 papers
Grants
- 2024–2029
Therapeutic Targeting for Translocation Renal Cell Carcinoma
National Cancer Institute · R01
Contact PI · $1.8M · State University of New York at Buffalo
- 2018–2025
Epigenetic Mechanisms of Drug Resistance in Renal Cell Carcinoma
National Cancer Institute · R01
Contact PI · $2.2M · State University of New York at Buffalo
- 2018–2023
Immunomodulation by Dietary Protein Restriction
National Cancer Institute · R21
Contact PI · $381.3K · State University of New York at Buffalo
- 2017–2023
Epigenetic Modulation of SEC24D and Circulating miR-605 in Renal Cell Carcinoma
National Cancer Institute · R21
Contact PI · $367.9K · State University of New York at Buffalo
Clinical trials
- 2024–2027
Principal investigator · Recruiting · Phase 1, Phase 2
State University of New York at Buffalo
- 2018–2024
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Principal investigator · Terminated · Phase 2
Roberto Pili
- 2018–2024
High Dose IL 2 and Entinostat in RCC
Principal investigator · Active not recruiting · Phase 2
Roberto Pili
- 2016–2017
Glycosylation of Exosomes in Prostate and Urothelial Carcinoma
Principal investigator · Terminated
Indiana University